Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Alliance Research Centers

Neither a doctor nor a teaching hospital

Research payments

$733,765

280 payments

Through program year 2025, Alliance Research Centers is reported as receiving $733,765 in research payments, across 280 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $4,387 3
2024 Research $14,157 10
2023 Research $11,392 6
2022 Research $27,948 17
2021 Research $43,643 16
2020 Research $132,823 53
2019 Research $499,415 175

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $195,685 28 payments
  2. Eisai Inc. $131,481 93 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $124,820 69 payments
  4. Noven Pharmaceuticals, Inc. $70,232 9 payments
  5. AbbVie, Inc. $69,623 32 payments
  6. Pfizer Inc. $39,578 23 payments
  7. Sanofi Pasteur Inc. $33,870 1 payment
  8. Aclaris Therapeutics, Inc. $32,210 7 payments
  9. Incyte Corporation $15,061 5 payments
  10. Corcept Therapeutics $11,833 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $131,481 93 payments
  2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Or Very Severe Alopecia Areata $110,666 7 payments
  3. M14-702 $66,865 29 payments
  4. BAY1454032 Essure System for Permanent Birth Control $63,505 13 payments
  5. A 24-Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of Azd3293 in Early Alzheimers Disease -The Amaranth Study $51,256 1 payment
  6. A 4-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Hp-5000 in Subjects With Osteoarthritis Oa of the Knee. $46,105 7 payments
  7. H 030 014 Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection $33,870 1 payment
  8. Randomized, Double-Blind, Vehicle-Controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Ati-502 Topical Solution Administered Twice-Daily for 6 Months in Adult Subjects With Stable Patchy Alopecia Areata $32,210 7 payments
  9. Jak1 Dupilumab Comparator Study $27,079 11 payments
  10. BAY1454032, Essure System for Permanent Birth Control $24,601 15 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record